Global Neurology Academy
The Global Neurology Academy (GNA) series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.
For more information about GNA, visit www.globalneurologyacademy.org.
211-225 of 253
Examining Schizophrenia Risk: The Influence of B12 Levels in Early Pregnancy
NeuroFrontiersExamining Schizophrenia Risk: The Influence of B12 Levels in Early Pregnancy
Unseen Struggles: Impacts of Homelessness on Women with Schizophrenia
NeuroFrontiersUnseen Struggles: Impacts of Homelessness on Women with Schizophrenia
NKX019: A Potential New Frontier in Generalized Myasthenia Gravis Therapy
NeuroFrontiersNKX019: A Potential New Frontier in Generalized Myasthenia Gravis Therapy
Beyond Amyloid and Tau: A Multimarker Approach to Alzheimer's Detection
NeuroFrontiersBeyond Amyloid and Tau: A Multimarker Approach to Alzheimer's Detection
Thomas Karikari, PhD
Debunking Misconceptions Regarding the Revised Alzheimer’s Diagnostic Criteria
NeuroFrontiersDebunking Misconceptions Regarding the Revised Alzheimer’s Diagnostic Criteria
Clifford Jack Jr., MD
Reviewing the Revised Alzheimer’s Diagnostic Criteria: The Role of Biomarkers
NeuroFrontiersReviewing the Revised Alzheimer’s Diagnostic Criteria: The Role of Biomarkers
Clifford Jack Jr., MD
- advertisement
5 Things You Need to Know About Epilepsy & Depression
CME/CE5 Things You Need to Know About Epilepsy & Depression
Heidi M. Munger Clary, MD, MPH
Jay Salpekar, MD, FANPA
Mind Matters: Psychiatric Comorbidity in the Prodromal Phase of MS
NeuroFrontiersMind Matters: Psychiatric Comorbidity in the Prodromal Phase of MS
Charles Turck, PharmD, BCPS, BCCCP
Anibal Chertcoff, MD
Diagnosing Suspected MS: A Review of the Updated Guidelines
NeuroFrontiersDiagnosing Suspected MS: A Review of the Updated Guidelines
Andrew Wilner, MD, FACP, FAAN
Eoin Flanagan, MB, BCh
Advances in Temporal Lobe Epilepsy Research
NeuroFrontiersAdvances in Temporal Lobe Epilepsy Research
Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Sanjay Kumar, PhD
Jerome Lisk, MD, MBA, M.S., FAAN
Mark Mintz, MD
Investigating the Link Between Hypertension Medications & Dementia
NeuroFrontiersInvestigating the Link Between Hypertension Medications & Dementia
Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Zachary Marcum, PharmD, PhD
- advertisement
B-Cell Therapy: When Is It Right for Our MS Patients?
NeuroFrontiersB-Cell Therapy: When Is It Right for Our MS Patients?
Charles Turck, PharmD, BCPS, BCCCP
Andrew Chan, MD
Alzheimer’s Disease: What’s The Latest Research?
NeuroFrontiersAlzheimer’s Disease: What’s The Latest Research?
Jerome Lisk, MD, MBA, M.S., FAAN
Peter Whitehouse, MD, PhD
Daniel George, MSc, PhD
Diving into the Debate Surrounding Aducanumab for Alzheimer’s
NeuroFrontiersDiving into the Debate Surrounding Aducanumab for Alzheimer’s
Jerome Lisk, MD, MBA, M.S., FAAN
Peter Whitehouse, MD, PhD